Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Jun 10–Jun 17, 2026)

· 1 min read

A quiet week on the trial calendar. On the Run-up Radar, UNCY leads with an FDA decision on its NDA 19 days out, followed by trial milestones for ADCT and IBRX about three weeks away. Last week’s biggest biotech gainer was TNGX, up 53% on 6.5 times its average volume.

📡 Run-up Radar Highlights

Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):

  • UNCY: NDA in 19 days, score 78/100
  • ADCT: Phase 3, Active Trial in 20 days, score 57/100
  • IBRX: Phase 2, Recruiting in 21 days, score 55/100

📈 Last Week’s Biggest Gainers

  • TNGX +52.97% (volume 6.5x average)
  • NUVL +39.28% (volume 77.0x average)

Track your tickers on the BioRadar dashboard →

This digest is for informational purposes only and is not investment advice. Always do your own research.

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.